Cargando…

Targeting “bad” B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?

Detalles Bibliográficos
Autores principales:	Forsthuber, Thomas G., Stuve, Olaf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032664/ https://www.ncbi.nlm.nih.gov/pubmed/27704037 http://dx.doi.org/10.1212/NXI.0000000000000283

Ejemplares similares

Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control?
por: Negron, Austin, et al.
Publicado: (2020)

Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review
por: Kolb-Sobieraj, Channa, et al.
Publicado: (2014)

Laquinimod in the treatment of multiple sclerosis: a review of the data so far
por: Thöne, Jan, et al.
Publicado: (2016)

Could Transcranial Direct Current Stimulation Join the Therapeutic Armamentarium in Obsessive-Compulsive Disorder?
por: Chalah, Moussa A., et al.
Publicado: (2020)

B-cell–targeted therapies in relapsing forms of MS
por: Dubey, Divyanshu, et al.
Publicado: (2017)

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree
por: Cutter, Gary R., et al.
Publicado: (2016)

B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets
por: Forsthuber, Thomas G., et al.
Publicado: (2018)

Bimekizumab: the new drug in the biologics armamentarium for psoriasis
por: Freitas, Egídio, et al.
Publicado: (2021)

A Growing Armamentarium for the Robotic Pancreas Surgeon?
por: Wilson, Gregory C.
Publicado: (2023)

Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea
por: Li, Zuohong, et al.
Publicado: (2020)

Laquinimod Supports Remyelination in Non-Supportive Environments
por: Nyamoya, Stella, et al.
Publicado: (2019)

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016)

Peripheral nerve axonal excitability studies: expanding the neurophysiologist’s armamentarium
por: Huynh, William, et al.
Publicado: (2015)

Community-acquired pneumonia: The need to broaden our diagnostic armamentarium
por: Perumal, R, et al.
Publicado: (2020)

Lysins – a new armamentarium for the treatment of bone and joint infections?
por: Sendi, Parham, et al.
Publicado: (2022)

Armamentarium and Sterilization
por: ELEAZER, PAUL D.
Publicado: (2011)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis
por: Moore, Spencer, et al.
Publicado: (2013)

The role of the complement system in Multiple Sclerosis: A review
por: Saez-Calveras, Nil, et al.
Publicado: (2022)

Cardiopulmonary exercise testing – A new addition to pre-anaesthetic armamentarium
por: Harsoor, SS, et al.
Publicado: (2010)

Expanding clinicians’ armamentarium for regional pain control after thoracic surgery
por: Tupper, Haley I., et al.
Publicado: (2023)

Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2017)

Clinical trials in multiple sclerosis: milestones
por: Zhang, Yinan, et al.
Publicado: (2018)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

Expanding the armamentarium for the spondyloarthropathies
por: Peloso, Paul M, et al.
Publicado: (2004)

The Modern Surgical Armamentarium
Publicado: (1873)

The American Armamentarium Chirurgicum
Publicado: (1889)

Evolution of clinical trials in multiple sclerosis
por: Zhang, Yinan, et al.
Publicado: (2019)

Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression
por: Varrin-Doyer, Michel, et al.
Publicado: (2016)

Editorial: Animal models of multiple sclerosis: can they advance future therapies?
por: DeSilva, Tara Maria, et al.
Publicado: (2023)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey, Divyanshu, et al.
Publicado: (2015)

Laquinimod reduces neuroaxonal injury through inhibiting microglial activation
por: Mishra, Manoj Kumar, et al.
Publicado: (2014)

Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake
por: Gentile, Antonietta, et al.
Publicado: (2018)

Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
por: Manouchehri, Navid, et al.
Publicado: (2021)

What's New in Critical Illness and Injury Science? Coagulants for local application in the surgical armamentarium!
por: Sharma, Shilpa
Publicado: (2016)

Procainamide for the Rapid Suppression of Premature Ventricular Contractions: An (Almost) Forgotten Tool in the Cardiologist’s Armamentarium
por: Muser, Daniele, et al.
Publicado: (2021)

Roentgen stereophotogrammetric analysis: still a very valuable tool in the orthopaedic research armamentarium
por: Fontalis, Andreas, et al.
Publicado: (2022)

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
por: Brück, Wolfgang, et al.
Publicado: (2012)

American Armamentarium Chirurgicum; Tieman
Publicado: (1889)

Allografts: expanding the surgeon’s armamentarium
por: Ahmed, Norus, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t5tne9tu2jgh55njgsvqu3rd71